MTOR and colorectal neoplasm: Work from our group has shown that BCL-3 promotes colorectal tumour cell survival and growth in vivo, through activation of the AKT pathway via phosphoinositide 3-kinase and mammalian target of rapamycin (mTOR) signalling (64).